[HTML][HTML] PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
A Parvez, F Choudhary, P Mudgal, R Khan… - Frontiers in …, 2023 - frontiersin.org
PD-1 (Programmed Cell Death Protein-1) and PD-L1 (Programmed Cell Death Ligand-1)
play a crucial role in regulating the immune system and preventing autoimmunity. Cancer …
play a crucial role in regulating the immune system and preventing autoimmunity. Cancer …
[HTML][HTML] Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems
Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
[HTML][HTML] A machine learning model based on PET/CT radiomics and clinical characteristics predicts tumor immune profiles in non-small cell lung cancer: a …
H Tong, J Sun, J Fang, M Zhang, H Liu, R Xia… - Frontiers in …, 2022 - frontiersin.org
Background The tumor immune microenvironment (TIME) phenotypes have been reported
to mainly impact the efficacy of immunotherapy. Given the increasing use of immunotherapy …
to mainly impact the efficacy of immunotherapy. Given the increasing use of immunotherapy …
[HTML][HTML] Recent advances in molecular mechanisms of cancer immunotherapy
Simple Summary The cancer-immunity cycle is characterized by various stimulatory and
inhibitory factors, which together regulate the immune response and halt the extreme …
inhibitory factors, which together regulate the immune response and halt the extreme …
[HTML][HTML] Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM
B Liu, Q Ji, Y Cheng, M Liu, B Zhang, Q Mei… - Journal of …, 2022 - Springer
Background Clinical studies have shown that the efficacy of programmed cell death receptor-
1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors on glioblastoma (GBM) is much …
1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors on glioblastoma (GBM) is much …
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy
Immunohistochemical assessment with combined positive score (CPS) of programmed
death-ligand 1 (PD-L1) is the prerequisite for administration of checkpoint inhibitor therapy …
death-ligand 1 (PD-L1) is the prerequisite for administration of checkpoint inhibitor therapy …
[HTML][HTML] Cutting-edge technology and automation in the pathology laboratory
One of the goals of pathology is to standardize laboratory practices to increase the precision
and effectiveness of diagnostic testing, which will ultimately enhance patient care and …
and effectiveness of diagnostic testing, which will ultimately enhance patient care and …
[HTML][HTML] Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma
Y Xu, X Hao, Y Ren, Q Xu, X Liu, S Song… - Frontiers in …, 2023 - frontiersin.org
Tumors meet their energy, biosynthesis, and redox demands through metabolic
reprogramming. This metabolic abnormality results in elevated levels of metabolites …
reprogramming. This metabolic abnormality results in elevated levels of metabolites …
[HTML][HTML] Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer
J Xu, S Chen, J Liang, T Hao, H Wang, G Liu… - Frontiers in …, 2022 - frontiersin.org
The Schlafen (SLFN) gene family plays an important role in immune cell differentiation and
immune regulation. Previous studies have found that the increased SLFN5 expression in …
immune regulation. Previous studies have found that the increased SLFN5 expression in …
Current approaches of immune checkpoint therapy in chronic lymphocytic leukemia
S Taghiloo, H Asgarian-Omran - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement Increasing understanding of the complex interaction between leukemic
and immune cells, which is responsible for tumor progression and immune evasion, has …
and immune cells, which is responsible for tumor progression and immune evasion, has …